EUCTR2012-004524-38-FR进行中（未招募）1 期
Phase III study comparing the efficacy of paclitaxel-bevacizumab with docetaxel in 2nd or 3rd line of treatment of non squamous Non Small Cells Lung Cancer - Ultimate
IFCT0 个研究点开始时间: 2013年5月21日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- 2nd or 3rd line of non squamous non small cell lung cancer of stage III or IV
- •- Document progression at the time of the inclusion. At least, one previous chemotherapy line with platinum. Patient who had previous treatment with bevacizumab can be included.
- •- Patient with active mutation of EGFR must have had on line of chemotherapy with platinum and one with Tyrosine kinase inhibitor of EGFR.
- •- Patient with ALK rearrangement must have had at least one line of chemotherapy with platinum and one with crizotinib.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 151
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 17
排除标准
- •- Mixed cancer small cells and non small cells or squamous lung cancer.
- •- Central nervous system symptomatic metastasis or requiring immediate cerebral radiotherapy
- •- patient who have had previous treatment with taxane (docetaxel, paclitaxel). Peri-operatory chemotherapy with taxane allowed if stopped more than 6 months before.
研究者
相似试验
终止
不适用
A phase III clinical study to compare paclitaxel (Genexol®-PM) in combination with standard therapy (gemcitabine/cisplatin) and standard therapy alone (gemcitabine/cisplatin) in patients with advanced biliary tractNeoplasmsKCT0003726Asan Medical Center220
进行中（未招募）
1 期
Prospective Randomized Phase-III-Trial of Paclitaxel plus Topotecan versus Topotecan plus Cisplatin in Recurrent or Persistent Cervical Carcinoma - AGO-Zervix-1Chemotherapeutical treatment of patients with recurrent or persistent or metastatic cervical carcinoma stage IVbEUCTR2006-000349-20-BEInstitut fuer Frauengesundheit GmbH173
进行中（未招募）
1 期
Patients in Recurrent or Persistent Cervical CarcinomaEUCTR2006-000349-20-DEInstitut fuer Frauengesundheit GmbH326
进行中（未招募）
不适用
Prospective Randomized Phase-III-Trial of Paclitaxel plus Topotecan versus Topotecan plus Cisplatin in Recurrent or Persistent Cervical Carcinoma - AGO-Zervix-1Chemotherapeutical treatment of patients with recurrent or persistent or metastatic cervical carcinoma stage IVbEUCTR2006-000349-20-ATInstitut fuer Frauengesundheit GmbH312
招募中
2 期
Phase II study of a Combination of Paclitaxel and 5'-DFUR in Patients with S-1 Failure Unresectable or Recurrent Gastric CancerAdvanced or recurrent gastric cancer previously treated with S-1JPRN-UMIN000008632Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine35